Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

This study identifies SOX9 as a critical downstream effector of ERG in TMPRSS2:ERG fusion-positive prostate cancer, indicating its role in tumor invasion and growth.

This study demonstrated that the antiandrogen drug enzalutamide may reduce TMPRSS2 levels in human lung cells and mouse lungs, supporting its potential as a COVID-19 treatment option.

This study found that the antiandrogens enzalutamide and bicalutamide reduced SARS-CoV-2 entry and infection in human lung cells by lowering TMPRSS2 levels, suggesting their potential as COVID-19 treatments and supporting clinical trials.

This study found that the antiandrogen drug enzalutamide reduced TMPRSS2 levels and significantly decreased SARS-CoV-2 entry and infection in lung cells, supporting further clinical trials for COVID-19 treatment.

This study found that lower testosterone levels in male COVID-19 patients were associated with greater disease severity and longer hospital stays.